You are confusing two different things. Being unhappy about the CEO doesn't equate to being unhappy about the investment. It isn't a difficult concept to understand but I can see how many can get it confused. I think the july 30-31st fiasco taught Gerald a very valuable lesson. But any experienced investor also knows that talk is cheap especially in the biotech space. It all comes down to a few things and that's typically FDA approval (or regulatory clearance) and product acceptance in the market place that generates revenue. The other big one is that company being bought out at a premium. I would gander that AMBS will eventually be bought out for its pipeline if the price is right.